Serum Hepatitis B Virus RNA as a Potential Diagnostic Biomarker During Chronic Hepatitis B Virus Infection

Cloherty, Gavin; Butler, Emily K.; Kuhns, Mary C.

doi:10.1002/cld.774

Cited by 13 publications

(18 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HBcrAg can be measured in the serum using an automated chemiluminescence assay 14 . HBV pregenomic RNA is transcribed from cccDNA and can be measured in the serum using polymerase chain reaction technique 15 . HBcrAg and HBV RNA have been shown to be strongly correlated with intrahepatic activity of cccDNA making them attractive markers to risk‐stratify HBV relapse after NA discontinuation 15–17 .…”

Section: Introductionmentioning

confidence: 99%

Novel viral markers and the prediction of off‐treatment relapse in chronic hepatitis B patients: A systematic review

Jaroenlapnopparat

Chayanupatkul

Tangkijvanich

2021

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim Hepatitis B core‐related antigen (HBcrAg) and hepatitis B virus RNA (HBV RNA) are novel markers that reflect intrahepatic cccDNA and could be useful in the prediction of relapse after nucleos(t)ide analogues (NA) discontinuation. The aim of the study is to perform a systematic review on this issue. Methods Medline/Pubmed database was searched using text terms related to HBcrAg, RNA, NAs, discontinuation, and relapse. Included studies were those that enrolled adult patients who had been on NAs for more than 6 months with available information on end‐of‐treatment (EOT) HBcrAg and/or HBV RNA and relapse rates. Results Sixteen studies were included. Virological and clinical relapse rates ranged from 11% to 100% and 11% to 73%, respectively. Low or undetectable EOT HBcrAg levels were associated with low off‐treatment relapse rates in most studies with area under the receiver operating characteristic curve (AUROC) of 0.69–0.70 for predicting virological relapse (VR) and 0.61–0.77 for predicting clinical relapse (CR). Undetectable EOT HBV RNA was associated with a lower risk of off‐treatment relapse with AUROC of 0.65–0.76 for predicting VR and 0.66–0.73 for predicting CR. Combined EOT HBcrAg and HBV RNA performed better in predicting off‐treatment relapse than either test alone with AUROC of 0.816–0.846 for predicting CR. None of the patients with double‐negative HBV RNA and HBcrAg developed CR. Conclusion Combining HBcrAg with HBV RNA or HBsAg improved the discriminating abilities in the prediction of off‐treatment relapse of each test. Patients with double‐negative HBcrAg and HBV RNA at EOT had low risks of relapse and could be considered for NA discontinuation.

show abstract

Section: Introductionmentioning

confidence: 99%

Novel viral markers and the prediction of off‐treatment relapse in chronic hepatitis B patients: A systematic review

Jaroenlapnopparat

Chayanupatkul

Tangkijvanich

2021

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…Both intracellular cccDNA and secreted HBV RNA point to the replicational activity of HBV [48,49]. cccDNA detection has some technical limitations, including complicated time-consuming tecniques, high costs and specificity concerns.…”

Section: Hbv Diagnostic Toolsmentioning

confidence: 99%

“…Two diagnostic tools that we previously mentioned could be used to pinpoint complete cure, cccDNA and serum HBV RNA. Of note, HBV RNA can be readily detected by very accurate and sensitive methods that are widely used in diagnostic laboratories [49].…”

Section: Hbv Treatmentmentioning

confidence: 99%

“…Moreover, as previously mentioned, on treatment qHBsAg levels have been used, together with HBV DNA decline and genotype, to design stopping rules for early pegIFN discontinuation in case of lack of response [31]. Additionally, HBV RNA could be used to predict response to pegIFN therapy [48,49].…”

Section: Hbv Treatmentmentioning

confidence: 99%

“…The high genetic barrier of TDF, TAF and ETV minimize the risk of virological failure, but genotypic testing is recommended in case of previous exposure to low genetic barrier NAs such as lamivudine, because of the risk of reduced susceptibility to ETV [64,65]. Among diagnostic tools, loss of RNA in subjects with undetectable HBV DNA could potentially serve as a new NA treatment endpoint alone or in conjunction with other markers [48,49].…”

Section: Hbv Treatmentmentioning

confidence: 99%

See 2 more Smart Citations

A Global View to HBV Chronic Infection: Evolving Strategies for Diagnosis, Treatment and Prevention in Immunocompetent Individuals

Nicolini

Orsi

Tatarelli

et al. 2019

IJERPH

View full text Add to dashboard Cite

Hepatitis B Virus (HBV) is a significant public health challenge. Around 250 million people live with chronic HBV infection. With a global approach to this issue, we focus on new perspective in diagnosis, management and prevention of HBV chronic infection. Precise diagnosis of HBV status is crucial to guide patient management. Although available drugs reduce the risk of liver disease progression, they are not able to definitely eradicate HBV, and new therapeutic options are urgently needed. Thus, prevention of HBV infection is still the most effective strategy to achieve the control of the disease. Key aspects of prevention programs include surveillance of viral hepatitis, screening programs and immunization strategies. In spite of the high success rate of licensed HBV vaccines, a need for improved vaccine persists, especially in order to provide coverage of current non-responders.

show abstract

Selective detection of HBV pre-genomic RNA in chronic hepatitis B patients using a novel RT-PCR assay

Nguyen,

Le Do,

et al. 2023

Clin Exp Med

View full text Add to dashboard Cite

Serum Hepatitis B Virus RNA as a Potential Diagnostic Biomarker During Chronic Hepatitis B Virus Infection

Abstract: http://aasldpubs.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2046-2484/video/13-3-reading-cloherty a video presentation of this article

Cited by 13 publications

References 13 publications

Novel viral markers and the prediction of off‐treatment relapse in chronic hepatitis B patients: A systematic review

Novel viral markers and the prediction of off‐treatment relapse in chronic hepatitis B patients: A systematic review

A Global View to HBV Chronic Infection: Evolving Strategies for Diagnosis, Treatment and Prevention in Immunocompetent Individuals

Selective detection of HBV pre-genomic RNA in chronic hepatitis B patients using a novel RT-PCR assay

Contact Info

Product

Resources

About